AMERICAN SHARED HOSPITAL SERVICES (AMS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.33%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -2.72×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.33% | Share-based compensation / revenue. Period ending 2026-06-30. $404.00K ÷ $30.41M × 100 ≈ 1.33% |
| Interest coverage · 12 months | -2.72× | Operating income ÷ reported interest expense. $-3.58M ÷ $1.32M ≈ -2.72× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 30.41M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 404.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -3.58M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 1.32M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $30.41M | $404.00K | $-3.58M | $1.32M | (m) | 1.33% | -2.72× | Reported |
| 2026-03-31 | (m) | $29.05M | $416.00K | $-3.21M | $1.44M | (m) | 1.43% | -2.23× | Reported |
| 2025-12-31 | (m) | $28.08M | $404.00K | $-3.59M | $1.57M | (m) | 1.44% | -2.28× | Reported |
| 2025-09-30 | (m) | $29.42M | $392.00K | $-4.02M | $1.68M | (m) | 1.33% | -2.39× | Reported |
| 2025-06-30 | (m) | $29.25M | $379.00K | $-4.56M | $1.63M | (m) | 1.30% | -2.81× | Reported |
| 2025-03-31 | (m) | $29.24M | $364.00K | $-4.02M | $1.58M | (m) | 1.25% | -2.54× | Reported |
| 2024-12-31 | (m) | $28.34M | $373.00K | $-2.81M | $1.50M | (m) | 1.32% | -1.87× | Reported |
| 2024-09-30 | (m) | $24.97M | $383.00K | $-568.00K | $1.36M | (m) | 1.53% | -0.42× | Reported |
| 2024-06-30 | (m) | $23.10M | $393.00K | $411.00K | $1.30M | (m) | 1.70% | 0.32× | Reported |
| 2024-03-31 | (m) | $21.62M | $391.00K | $87.00K | $1.19M | (m) | 1.81% | 0.07× | Reported |
| 2023-12-31 | (m) | $21.32M | $389.00K | $270.00K | $1.11M | (m) | 1.82% | 0.24× | Reported |
| 2023-09-30 | (m) | $20.66M | $455.00K | $453.00K | $1.08M | (m) | 2.20% | 0.42× | Reported |
| 2023-06-30 | (m) | $20.36M | $433.00K | $811.00K | $1.06M | (m) | 2.13% | 0.77× | Reported |
| 2023-03-31 | (m) | $19.82M | $408.00K | $1.93M | $929.00K | (m) | 2.06% | 2.08× | Reported |
| 2022-12-31 | (m) | $19.75M | $399.00K | $2.43M | $806.00K | (m) | 2.02% | 3.02× | Reported |
| 2022-09-30 | (m) | $19.40M | $343.00K | $2.56M | $698.00K | (m) | 1.77% | 3.67× | Reported |
| 2022-06-30 | (m) | $18.67M | $376.00K | $2.30M | $611.00K | (m) | 2.01% | 3.77× | Reported |
| 2022-03-31 | (m) | $18.11M | $400.00K | $1.86M | $627.00K | (m) | 2.21% | 2.97× | Reported |
| 2021-12-31 | (m) | $17.63M | $420.00K | $1.35M | $739.00K | (m) | 2.38% | 1.83× | Reported |
| 2021-09-30 | (m) | $17.55M | $422.00K | $-7.92M | $841.00K | (m) | 2.40% | -9.41× | Reported |
| 2021-06-30 | (m) | $18.12M | $393.00K | $-8.35M | $933.00K | (m) | 2.17% | -8.95× | Reported |
| 2021-03-31 | (m) | $17.63M | (m) | $-9.27M | $1.03M | (m) | (m) | -8.96× | Reported |
| 2020-12-31 | (m) | $17.84M | $299.00K | $-9.46M | $1.06M | (m) | 1.68% | -8.95× | Reported |
| 2020-09-30 | (m) | $18.02M | (m) | $-641.00K | $1.11M | (m) | (m) | -0.58× | Reported |
| 2020-06-30 | (m) | $18.65M | (m) | $56.00K | $1.15M | (m) | (m) | 0.05× | Reported |
| 2020-03-31 | (m) | $19.85M | $231.00K | $928.00K | $1.23M | (m) | 1.16% | 0.75× | Reported |
| 2019-12-31 | (m) | $20.61M | $230.00K | $1.54M | $1.32M | (m) | 1.12% | 1.17× | Reported |
| 2019-09-30 | (m) | $20.59M | $224.00K | $1.50M | $1.42M | (m) | 1.09% | 1.06× | Reported |
| 2019-06-30 | (m) | $19.76M | $219.00K | $1.24M | $1.51M | (m) | 1.11% | 0.82× | Reported |
| 2019-03-31 | (m) | $19.73M | $223.00K | $1.58M | $1.57M | (m) | 1.13% | 1.01× | Reported |
| 2018-12-31 | (m) | $19.71M | $223.00K | $1.86M | $1.63M | (m) | 1.13% | 1.14× | Reported |
| 2018-09-30 | (m) | (m) | $334.00K | $2.17M | $1.84M | (m) | (m) | 1.18× | Reported |
| 2018-06-30 | (m) | (m) | $335.00K | $2.43M | $1.86M | (m) | (m) | 1.31× | Reported |
| 2018-03-31 | (m) | (m) | $328.00K | $2.45M | $1.90M | (m) | (m) | 1.29× | Reported |
| 2017-12-31 | (m) | (m) | $323.00K | $2.41M | $1.93M | (m) | (m) | 1.25× | Reported |
| 2017-09-30 | (m) | (m) | $212.00K | $3.31M | $1.80M | (m) | (m) | 1.84× | Reported |
| 2017-06-30 | (m) | (m) | $196.00K | $3.77M | $1.89M | (m) | (m) | 2.00× | Reported |
| 2017-03-31 | (m) | (m) | $206.00K | $3.54M | $1.88M | (m) | (m) | 1.89× | Reported |
| 2016-12-31 | (m) | (m) | $215.00K | $3.29M | $1.71M | (m) | (m) | 1.93× | Reported |
| 2016-09-30 | (m) | (m) | $235.00K | $2.57M | $1.56M | (m) | (m) | 1.65× | Reported |
| 2016-06-30 | (m) | (m) | $251.00K | $1.99M | $1.29M | (m) | (m) | 1.54× | Reported |
| 2016-03-31 | (m) | (m) | $249.00K | $2.02M | $1.20M | (m) | (m) | 1.68× | Reported |
| 2015-12-31 | (m) | (m) | $226.00K | $1.98M | $1.24M | (m) | (m) | 1.60× | Reported |
| 2015-09-30 | (m) | (m) | $237.00K | $1.63M | $1.22M | (m) | (m) | 1.33× | Reported |
| 2015-06-30 | (m) | (m) | $186.00K | $1.59M | $1.38M | (m) | (m) | 1.15× | Reported |
| 2015-03-31 | (m) | (m) | $148.00K | $509.00K | $1.55M | (m) | (m) | 0.33× | Reported |
| 2014-12-31 | (m) | (m) | $138.00K | $-50.00K | $1.70M | (m) | (m) | -0.03× | Reported |
| 2014-09-30 | (m) | (m) | $72.00K | $-169.00K | $1.72M | (m) | (m) | -0.10× | Reported |
| 2014-06-30 | (m) | (m) | $77.00K | $-281.00K | $1.85M | (m) | (m) | -0.15× | Reported |
| 2014-03-31 | (m) | (m) | $77.00K | $605.00K | $1.80M | (m) | (m) | 0.34× | Reported |
| 2013-12-31 | (m) | (m) | $88.00K | $1.12M | $1.80M | (m) | (m) | 0.62× | Reported |
| 2013-09-30 | (m) | (m) | $81.00K | $914.00K | $1.98M | (m) | (m) | 0.46× | Reported |
| 2013-06-30 | (m) | (m) | $72.00K | $962.00K | $1.97M | (m) | (m) | 0.49× | Reported |
| 2013-03-31 | (m) | (m) | $79.00K | $903.00K | $2.05M | (m) | (m) | 0.44× | Reported |
| 2012-12-31 | (m) | (m) | $74.00K | $730.00K | $2.15M | (m) | (m) | 0.34× | Reported |
| 2012-09-30 | (m) | (m) | $85.00K | $999.00K | $2.25M | (m) | (m) | 0.44× | Reported |
| 2012-06-30 | (m) | (m) | $107.00K | $1.60M | $2.33M | (m) | (m) | 0.69× | Reported |
| 2012-03-31 | (m) | (m) | $119.00K | $1.60M | $2.37M | (m) | (m) | 0.68× | Reported |
| 2011-12-31 | (m) | (m) | $125.00K | $1.59M | $2.37M | (m) | (m) | 0.67× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $110.00K | $865.00K | $2.10M | (m) | (m) | 0.41× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $135.00K | $653.00K | $2.06M | (m) | (m) | 0.32× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |